It’s official --OXGN’s CA4P won’t be used as a systemic drug in AMD:
This was reported by ‘jrnpanther,’ one of the posters on the Yahoo board who attended OXGN’s annual meeting on Thursday. For anyone who has been reading this message board for a while, this is absolutely no surprise.
Moral: when it comes to clinical-development programs, watch the rate of patient enrollment. If a trial is for a common disease (such as AMD) and it takes place at a respected venue (such as Johns Hopkins) patients should be queued up to enroll. If enrollment is nevertheless proceeding at a snail’s pace, you have a problem even if management tells investors that everything is normal.
Market Data 
Markets 
AI
